CorMedix Inc. (CRMD) Director Buys $75,110.56 in Stock
CorMedix Inc. (NYSEAMERICAN:CRMD) Director Janet Dillione acquired 11,144 shares of the company’s stock in a transaction on Wednesday, May 15th. The shares were purchased at an average cost of $6.74 per share, for a total transaction of $75,110.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Janet Dillione also recently made the following trade(s):
- On Monday, March 18th, Janet Dillione acquired 42,000 shares of CorMedix stock. The shares were purchased at an average cost of $1.67 per share, for a total transaction of $70,140.00.
Shares of NYSEAMERICAN CRMD traded up $0.59 during midday trading on Friday, reaching $7.33. 661,313 shares of the company were exchanged, compared to its average volume of 567,378. CorMedix Inc. has a 1 year low of $0.85 and a 1 year high of $13.70.
A number of institutional investors and hedge funds have recently made changes to their positions in CRMD. BlackRock Inc. boosted its holdings in CorMedix by 374.4% in the 4th quarter. BlackRock Inc. now owns 2,656,672 shares of the biotechnology company’s stock valued at $3,427,000 after purchasing an additional 2,096,663 shares in the last quarter. Vanguard Group Inc boosted its holdings in CorMedix by 49.7% in the 3rd quarter. Vanguard Group Inc now owns 2,673,113 shares of the biotechnology company’s stock valued at $2,589,000 after purchasing an additional 886,894 shares in the last quarter. Vanguard Group Inc. boosted its holdings in CorMedix by 49.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,673,113 shares of the biotechnology company’s stock valued at $2,589,000 after purchasing an additional 886,894 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in CorMedix by 300.1% in the 4th quarter. Bank of New York Mellon Corp now owns 150,689 shares of the biotechnology company’s stock valued at $194,000 after purchasing an additional 113,029 shares in the last quarter. Finally, EAM Global Investors LLC purchased a new stake in CorMedix in the 1st quarter valued at approximately $940,000.
A number of equities analysts recently issued reports on CRMD shares. Zacks Investment Research raised CorMedix from a “sell” rating to a “hold” rating in a report on Tuesday, February 12th. HC Wainwright reissued a “buy” rating and set a $17.50 price target on shares of CorMedix in a report on Friday, January 18th.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2019/05/18/cormedix-inc-crmd-director-buys-75110-56-in-stock.html.
CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.
Recommended Story: What is the Producer Price Index (PPI)?
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.